Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Andrea Janikova, MD, PhD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Leos Kren, MD, PhD, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Jan Pirnos, MD, Milan Matuska, MD, PhD, Tomas Papajik, MD, PhD, ass. prof., Heidi Mocikova, MD, PhD, Samuel Vokurka, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4387.

https://doi.org/10.1182/blood.V122.21.4387.4387

Published: 2013

Journal Articles

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Andrea Janikova, MD, PhD, Katerina Benesova, MD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Natasa Kopalova, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Samuel Vokurka, MD, PhD, Jan Pirnos, MD, Milan Matuska, MD, PhD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4388.

https://doi.org/10.1182/blood.V122.21.4388.4388

Published: 2013

Journal Articles

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Vit Prochazka, M.D., Ph.D., Marek Trneny, MD, Ph.D., Prof., Andrea Janikova, MD, PhD, David Belada, M.D., Ph.D., Tomas Kozak, M.D., Ph.D., ass. prof., Tomas Papajik, MD, PhD, ass. prof., Vit Campr, MD, Ph.D., David Salek, MD, Ph.D., Robert Pytlik, MD, Ph.D., Alice Sykorova, MD, PhD, Milada Jankovska, MD, Jitka Dlouha

Blood (2013) 122 (21): 4354.

https://doi.org/10.1182/blood.V122.21.4354.4354

Published: 2013

Journal Articles

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Vit Prochazka, M.D., Ph.D., Martin Novák, Dr., Zuzana Pikalova, Dr., Tomas Papajik, Dr., Ph.D., Karel Indrak, MD, Prof., Vladimir Divoky, Ph.D., ass. prof.

Blood (2012) 120 (21): 2670.

https://doi.org/10.1182/blood.V120.21.2670.2670

Published: 2012

Journal Articles

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Vit Prochazka, M.D., Ph.D., Tomas Papajik, Dr., Ph.D., Patrik Flodr, Dr., Pavla Latalova, Dr., Zuzana Prouzova, Dr., Radka Nedomova, Mgr., Marie Jarosova, Prof., Vladimir Divoky, Ph.D., ass. prof., Karel Indrak, MD, Prof.

Blood (2012) 120 (21): 2671.

https://doi.org/10.1182/blood.V120.21.2671.2671

Published: 2012

NARROW

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Email alerts

ASH Publications

American Society of Hematology

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only